Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Conte

Showing results (211-220 of 247) with videos related to

Pageof 25
Sort By:
Frontiers in Immunology|December 19, 2022
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccineFederica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology|December 28, 2023
Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patientsIvan Arisi, Leonardo Malimpensa, Valeria Manzini, et al.
Journal of Neurology|January 26, 2021
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosisMatteo Lucchini, Luca Prosperini, Maria Chiara Buscarinu, et al.
Journal of Neurology|July 10, 2026
Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 studyMassimo Filippi, Luigi M E Grimaldi, Vincenzo Brescia Morra, et al.
Parkinsonism & Related Disorders|July 8, 2026
Rapidly progressive dementia with parkinsonism in the Italian CJD Registry: underlying pathology and clinical-biomarker clues for differential diagnosisMatteo Costanzo, Luana Vaianella, Anna Poleggi, et al.
Parkinsonism & Related Disorders|May 8, 2022
Relationship between risk and protective factors and clinical features of Parkinson's diseaseDaniele Belvisi, Roberta Pellicciari, Andrea Fabbrini, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 10, 2022
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort studyMaria Antonella Zingaropoli, Patrizia Pasculli, Marco Iannetta, et al.
Journal of Clinical Medicine|January 21, 2022
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive TreatmentCarla Prezioso, Marco Ciotti, Gabriele Brazzini, et al.
Multiple Sclerosis and Related Disorders|March 11, 2023
Frailty and relapse activity in multiple sclerosis: A longitudinal observationViola Baione, Marco Canevelli, Daniele Belvisi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 5, 2025
The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies EvaluationTommaso Guerra, Massimiliano Copetti, Chiara Zanetta, et al.
Pageof 25

Showing results (211-220 of 247) with videos related to

Sort By:
Pageof 25
Frontiers in Immunology|December 19, 2022
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccineFederica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology|December 28, 2023
Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patientsIvan Arisi, Leonardo Malimpensa, Valeria Manzini, et al.
Journal of Neurology|January 26, 2021
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosisMatteo Lucchini, Luca Prosperini, Maria Chiara Buscarinu, et al.
Journal of Neurology|July 10, 2026
Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 studyMassimo Filippi, Luigi M E Grimaldi, Vincenzo Brescia Morra, et al.
Parkinsonism & Related Disorders|July 8, 2026
Rapidly progressive dementia with parkinsonism in the Italian CJD Registry: underlying pathology and clinical-biomarker clues for differential diagnosisMatteo Costanzo, Luana Vaianella, Anna Poleggi, et al.
Parkinsonism & Related Disorders|May 8, 2022
Relationship between risk and protective factors and clinical features of Parkinson's diseaseDaniele Belvisi, Roberta Pellicciari, Andrea Fabbrini, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 10, 2022
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort studyMaria Antonella Zingaropoli, Patrizia Pasculli, Marco Iannetta, et al.
Journal of Clinical Medicine|January 21, 2022
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive TreatmentCarla Prezioso, Marco Ciotti, Gabriele Brazzini, et al.
Multiple Sclerosis and Related Disorders|March 11, 2023
Frailty and relapse activity in multiple sclerosis: A longitudinal observationViola Baione, Marco Canevelli, Daniele Belvisi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 5, 2025
The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies EvaluationTommaso Guerra, Massimiliano Copetti, Chiara Zanetta, et al.
Pageof 25